<DOC>
	<DOCNO>NCT02356679</DOCNO>
	<brief_summary>The purpose study evaluate Efficacy Safety EUPASIDIN-S Tab . Gastritis Patients .</brief_summary>
	<brief_title>Efficacy Safety Eupasidin-s Tab . ( EUPASIDIN-S ) Gastritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Gastritis</mesh_term>
	<criteria>1 . Age 19 year old , men woman 2 . Patients diagnose acute chronic gastritis gastroscopy need treatment gastritis symptom 3 . Patients one erosion find gastroscopy 4 . Patients voluntarily sign write informed consent may participate study 1 . Patients peptic ulcer gastroesophageal reflux disease 2 . Patients Gastrointestinal malignant tumor surgery relate stomach resection 3 . Patients thromboembolism coagulation disorder 4 . Patients significant cardiovascular , pulmonary , heptic , renal primary disease 5 . Patients abnormal laboratory result screen Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) , Creatinine &gt; upper limit normal range x 2 White blood cell ( WBC ) &lt; 4,000/mm3 Platelet &lt; 50,000/mm3 6 . Patients administer H2 receptor antagonist , proton pump inhibitor , muscarine receptor antagonist , gastiritis treatment drug , protective factor builder , nonsteroid antiinflammatory drug prior study 2 week 7 . History allergic reaction investigational product 8 . Women either pregnant , breast feeding possible pregnant without contraceptive method 9 . Use investigational drug within 3 month prior study 10 . Patients investigator consider ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>